Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell cult...
Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry
About this item
Full title
Author / Creator
Morin-Dewaele, Margot , Bartier, Sophie , Berry, François , Brillet, Rozenn , López-Molina, Dennis Salomón , Nguyễn, Công Trung , Maille, Pascale , Sereno, Kevin , Nevers, Quentin , Softic, Laurent , Vaugeois, Jean-Marie , Louis, Bruno , Bequignon, Emilie , Bruscella, Patrice , Coste, André , Pawlotsky, Jean-Michel , Jamain, Stéphane and Ahmed-Belkacem, Abdelhakim
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The 2019 global coronavirus (COVID-19) pandemic has brought the world to a grinding halt, highlighting the urgent need for therapeutic and preventive solutions to slow the spread of emerging viruses. The objective of this study was to assess the anti-SARS-CoV-2 effectiveness of 8 FDA-approved cationic amphiphilic drugs (CADs). SARS-CoV-2-infected V...
Alternative Titles
Full title
Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry
Authors, Artists and Contributors
Author / Creator
Bartier, Sophie
Berry, François
Brillet, Rozenn
López-Molina, Dennis Salomón
Nguyễn, Công Trung
Maille, Pascale
Sereno, Kevin
Nevers, Quentin
Softic, Laurent
Vaugeois, Jean-Marie
Louis, Bruno
Bequignon, Emilie
Bruscella, Patrice
Coste, André
Pawlotsky, Jean-Michel
Jamain, Stéphane
Ahmed-Belkacem, Abdelhakim
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b2427bee83c4498fb02b4dfaebe3767d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b2427bee83c4498fb02b4dfaebe3767d
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-022-25399-5
